Medicare Part D's Effects on Elderly Patients' Drug Costs and Utilization

被引:0
|
作者
Ketcham, Jonathan D. [1 ]
Simon, Kosali I. [2 ]
机构
[1] Arizona State Univ, Sch Hlth Management & Policy, WP Carey Sch Business, Tempe, AZ 85287 USA
[2] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2008年 / 14卷 / 11期
关键词
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To analyze Medicare Part D's net effect on elderly patients' use of and out-of-pocket (OOP) costs for prescription drugs and to compare these with standardized results from prior studies. Study Design: Our dataset contains 1.4 billion prescriptions from Wolters Kluwer Health from December 2004 through December 2007 for patients whose age as of 2007 was more than 57 years. Methods: Days' supply per capita, OOP cost per day's supply, and number of individuals filling prescriptions were compared before and after January 2006 for those over age 66 years versus those age 58-64 years. Adjustment was made for under-reporting of pure cash prescriptions in the data. Results: Elderly patients' utilization in the first year of Part D increased compared with that of supply near-elderly patients by 8.1% for days and 4.8% for the number of individuals filling prescriptions, and their OOP costs declined by 172%. Although elderly patients' OOP costs in the second year were reduced an additional 5.8%, days' supply increased by only an additional 1.0%. Correcting for the under-reporting of pure cash prescriptions yielded effects of 8.1% and -3.5% for days' supply and -15.6% and -7.2% for COP costs in 2006 and 2007, respectively. A standardized comparison with previous estimates from Walgreens data showed that our utilization estimates were 2.6 times larger. Conclusion: Part D lowered elderly patients' OOP costs and increased utilization, primarily during the first year of the program. Magnitudes vary substantially across studies because of differences in data and methods.
引用
收藏
页码:SP14 / SP22
页数:9
相关论文
共 50 条
  • [31] Medicare Part D and the Financial Protection of the Elderly
    Engelhardt, Gary V.
    Gruber, Jonathan
    AMERICAN ECONOMIC JOURNAL-ECONOMIC POLICY, 2011, 3 (04) : 77 - 102
  • [32] Health care utilization by medicare advantage beneficiaries in the era of the medicare part D drug benefit coverage gap
    Delate, T.
    Raebel, M. A.
    Ellis, J. L.
    Bayliss, E. A.
    VALUE IN HEALTH, 2008, 11 (03) : A12 - A12
  • [33] IMPACT OF THE MEDICARE PART D COVERAGE GAP ON PRESCRIPTION DRUG UTILIZATION AND MEDICATION ADHERENCE
    Naik, R.
    Borrego, M.
    Dodd, M.
    Raisch, D.
    Khan, N.
    Bakhireva, L.
    Gupchup, G.
    Cunico, L.
    VALUE IN HEALTH, 2011, 14 (03) : A24 - A24
  • [34] The new medicare part D prescription drug benefit: An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation
    Evans-Molina, Carmella
    Regan, Susan
    Henault, Lori E.
    Hylek, Elaine M.
    Schwartz, Gregory R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (07) : 1038 - 1043
  • [35] Antipsychotic Drug Use and Adherence - Treatment for the Elderly Under the Medicare Part D Program
    Hsu, John
    Price, Mary
    Fung, Vicki
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2009, 12 : S21 - S22
  • [36] Regions With Higher Medicare Part D Spending Show Better Drug Adherence, But Not Lower Medicare Costs For Two Diseases
    Stuart, Bruce
    Shoemaker, J. Samantha
    Dai, Mingliang
    Davidoff, Amy J.
    HEALTH AFFAIRS, 2013, 32 (01) : 120 - 126
  • [37] Per-patient-per-month Drug Costs in Medicare Part D Protected Classes
    Lisa Mucha
    Neal A. Masia
    Kirsten J. Axelsen
    PharmacoEconomics, 2006, 24 : 79 - 84
  • [38] Per-patient-per-month drug costs in Medicare Part D protected classes
    Mucha, L.
    Axelsen, K. J.
    Masia, N.
    VALUE IN HEALTH, 2007, 10 (03) : A4 - A4
  • [39] Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's
    Yang Zhao
    Tzu-Chun Kuo
    Sharada Weir
    Marilyn S Kramer
    Arlene S Ash
    BMC Health Services Research, 8
  • [40] Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments
    Arambadjis, Yorgos
    Butler, Mary
    Huckfeldt, Peter
    Schondelmeyer, Stephen
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020, 16 (09): : 1290 - 1293